newsfilter
← Latest News
Business Wire·

Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role

Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Jane Pritchett Henderson, previously a member of Sesen Bio's Board of Directors and th